Lung Adenocarcinoma, Stage I Clinical Trial
Official title:
Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm
A single center, open-label, single arm study in patients who have solid or micropapillary adenocarcinoma with pathologic stage I and primary tumor no more than 4 cm. Pembrolizumab 200 mg every 3 weeks
This is a single center, open-label, single arm study in patients who have solid or micropapillary adenocarcinoma with pathologic stage I and primary tumor no more than 4 cm. Patients will be treated with pembrolizumab 200 mg every 3 weeks till 1 year or disease recurrence or intolerable toxicity. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03351842 -
Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%
|
Phase 2 | |
| Recruiting |
NCT05830812 -
Improving the Intraoperative Diagnosis Accuracy of Invasiveness for Small-sized Lung Adenocarcinoma
|
||
| Recruiting |
NCT04944173 -
SCION: SABR and Checkpoint Inhibition Of NSCLC
|
Phase 2 | |
| Recruiting |
NCT02951897 -
Application of Detecting Circulating Tumor Cells in the Accurate Treatment of Early Stage Lung Adenocarcinoma
|
N/A |